Thomas A. Satterfield, Jr. Decreases Stake in Coherus Oncology, Inc. Below 5% Threshold

Thomas A. Satterfield, Jr. filed an amended Schedule 13G (Amendment No. 1) for Coherus Oncology, Inc. (CHRS), reporting a beneficial ownership of 6,930,000 shares, which represents approximately 4.6% of the company's common stock. This filing indicates a decrease in ownership below the 5% reporting threshold, as the previous ownership percentage was not explicitly detailed but the filer has now checked the box indicating they have ceased to be the beneficial owner of more than 5 percent of the class of securities. The reported shares include various holdings: 115,000 shares held jointly with his spouse, 800,000 shares via Tomsat Investment & Trading Co., 2,100,000 shares via Caldwell Mill Opportunity Fund, and 1,750,000 shares via A.G. Family L.P. Additionally, Mr. Satterfield holds limited powers of attorney for voting and disposition over 2,165,000 shares held by various family members and trusts. The filing was triggered by events as of March 31, 2026, and confirms the shares are held for investment purposes without the intent to influence control of the issuer.